Pulmonx (NASDAQ:LUNG – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare Pulmonx to similar businesses based on the strength of its earnings, valuation, institutional ownership, analyst recommendations, dividends, profitability and risk.
Insider and Institutional Ownership
91.0% of Pulmonx shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Pulmonx and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Pulmonx | $88.78 million | -$54.00 million | -2.84 |
| Pulmonx Competitors | $1.89 billion | $135.83 million | 5.78 |
Pulmonx’s peers have higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a breakdown of recent recommendations for Pulmonx and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 1 | 0 | 3 | 0 | 2.50 |
| Pulmonx Competitors | 4311 | 10598 | 18391 | 838 | 2.46 |
Pulmonx currently has a consensus price target of $7.67, suggesting a potential upside of 167.60%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.46%. Given Pulmonx’s stronger consensus rating and higher probable upside, analysts clearly believe Pulmonx is more favorable than its peers.
Profitability
This table compares Pulmonx and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -47.93% | -98.23% | -35.89% |
| Pulmonx Competitors | -270.28% | -155.47% | -22.38% |
Volatility & Risk
Pulmonx has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Pulmonx’s peers have a beta of 2.58, meaning that their average share price is 158% more volatile than the S&P 500.
Summary
Pulmonx peers beat Pulmonx on 7 of the 13 factors compared.
About Pulmonx
Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company’s Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
